SLC5A2 and hydrops fetalis: When stratified by regions, SGLT2-Is vs. placebo reduced the risk of the composite outcome of CVD death/HF hospitalisation for the regions of North America (n = 4 studies) and Europe (n = 5 studies), with no strong evidence of an effect for South/Central America (n = 4 studies), Asia (n = 1 study), Pacific (n = 1 study), Asia/Pacific (n = 2 studies) and Africa (n = 1 study): HRs (95% CIs) of 0.80 (0.69–0.92), 0.81 (0.72–0.91), 0.81 (0.64–1.01), 0.96 (0.50–1.86), 0.92 (0.31–2.74), 0.96 (0.67–1.38) and 1.00 (0.53–1.90), respectively (Supplementary Appendix 7).